Immunovant, Inc.

IMVT · Nasdaq · United States

Share price · IMVT

$33.17-11.13 (-25.12%) 3M

close as of 2026-11-18 · 24h delayed · vol 908K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IMVT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026+15.1%
  2. 6 Nov 2026+7.5%
  3. 8 Oct 2026-5.6%

    Nothing announced by IMVT that day or the session before.

  4. 23 Sep 2026-7.4%
  5. 20 May 2026+35.3%

    Nothing announced by IMVT that day or the session before.

  6. 8 May 2026+6.3%
  7. 17 Apr 2026+7.1%

    Nothing announced by IMVT that day or the session before.

  8. 23 Mar 2026+6.1%
  9. 6 Feb 2026+12.4%

    Nothing announced by IMVT that day or the session before.

Share of unusual movement by asset

For each asset, the share of IMVT's own-move activity since 15 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Imeroprubart
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—6%
Sessions with no dated event—93%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
FcRnMonoclonal antibody
Rheumatoid ArthritisMyasthenia GravisGraves' DiseaseChronic Inflammatory Demyelinating PolyneuropathySjögren's Disease

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
May 2027 (1)
ImeroprubartPhase 2Graves' Disease
Est. primary completion 2027-05 · NCT07018323 · CT.gov ↗
What to watch
September 2027 (1)
ImeroprubartPhase 2Rheumatoid Arthritis
Est. primary completion 2027-09 · NCT06754462 · CT.gov ↗
What to watch
December 2027 (1)
ImeroprubartPhase 3Generalized Myasthenia Gravis
Est. primary completion 2027-12 · NCT07039916 · CT.gov ↗
What to watch
2028 (3)
June 2028 (1)
ImeroprubartPhase 2Graves' Disease
Est. primary completion 2028-06 · NCT06727604 · CT.gov ↗
What to watch
July 2028 (1)
ImeroprubartPhase 2Primary Sjögren's Syndrome
Est. primary completion 2028-07 · NCT06979531 · CT.gov ↗
What to watch
August 2028 (1)
ImeroprubartPhase 2Chronic Inflammatory Demyelinating Polyneuropathy
Est. primary completion 2028-08 · NCT07032662 · CT.gov ↗
What to watch
2030 (1)
March 2030 (1)
ImeroprubartPhase 2Graves' Disease
Est. primary completion 2030-03 · NCT07286006 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

November 2026Topline resultImeroprubartRandomized withdrawal period (Period 2) in difficult-to-treat RA met its primary endpoint

Recent

23 September 2026Topline resultIMVT-1402IMVT-1402 CLE proof-of-concept study misses primary endpoint; CLE development stopped
Immunovant, Inc. · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$85M$722M$97M-$83M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$143M$798M$153M-$124M operating cash flowreport ↗
2025-Q4—$99M$995M$111M-$92M operating cash flowreport ↗
2025-Q3—$114M$522M$127M-$103M operating cash flowreport ↗
2025-Q2—$101M$599M$121M-$117M operating cash flowreport ↗
2024-Q4—$95M$375M$111M-$100M operating cash flowreport ↗
2024-Q3—$97M$473M$109M-$89M operating cash flowreport ↗
2024-Q2—$75M$560M$87M-$76M operating cash flowreport ↗
2023-Q4—$48M$691M$51M-$47M operating cash flowreport ↗
2023-Q3—$48M$270M$59M-$60M operating cash flowreport ↗
2023-Q2—$51M$330M$74M-$47M operating cash flowreport ↗
2022-Q4—$42M$433M$63M-$46M operating cash flowreport ↗
2022-Q3—$38M$406M$48M-$20M operating cash flowreport ↗
2022-Q2—$28M$427M$40M-$66M operating cash flowreport ↗
2021-Q4—$30M$527M$41M-$32M operating cash flowreport ↗

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY—$457M$902M$126M-$407M operating cash flowreport ↗
View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$361M$714M$103M-$376M operating cash flowreport ↗
2024-FY—$213M$635M$65M-$214M operating cash flowreport ↗
2023-FY—$160M$377M$53M-$188M operating cash flowreport ↗
2022-FY—$102M$494M$39M-$106M operating cash flowreport ↗
2021-FY——$400M$27M-$83M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($350.0M), 61 sales ($16.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-11Pande Atul · directorOption exercise3,000$8.43$25KForm 4
2026-11-11Pande Atul · directorOpen-market sale3,000$36.00$108KForm 4
2026-11-11Pande Atul · directorOption exercise (derivative)3,000——Form 4
2026-10-28Girao Tiago · Chief Financial OfficerOpen-market sale6,606$28.50$188KForm 4
2026-10-21Stout Jay S · Chief Technology OfficerOpen-market sale2,595$28.94$75KForm 4
2026-10-07Gloria Melanie · Chief Operating OfficerOpen-market sale2,241$32.06$72KForm 4
2026-10-07Van Tuyl Christopher · Chief Legal OfficerOpen-market sale1,327$32.06$43KForm 4
2026-10-07Stout Jay S · Chief Technology OfficerOpen-market sale2,213$32.06$71KForm 4